BioLife Solutions Reports Third Quarter 2025 Financial Results
BioLife Solutions (Nasdaq: BLFS) reported Q3 2025 results showing continued growth in its core cell processing business. Cell Processing revenue rose 33% YoY to $25.4M, total revenue was $28.1M (up 31% YoY), and adjusted EBITDA was $7.8M (28% of revenue). GAAP net income for Q3 was $0.6M. Management raised 2025 Cell Processing revenue guidance to $93.0M–$94.0M and total revenue guidance (post-evo sale) to $95.0M–$96.0M. The company completed the sale of its evo cold chain business for $25.5M in early October 2025.
BioLife Solutions (Nasdaq: BLFS) ha riportato i risultati del Q3 2025 mostrando una crescita continua nel suo core business di processamento cellulare. Le entrate del Processing cellulare sono salite del 33% su base annua a 25,4 milioni di dollari, le entrate totali sono state di 28,1 milioni di dollari (in aumento del 31% su base annua), e l'EBITDA rettificato è stato di 7,8 milioni di dollari (28% delle entrate). l'utile netto GAAP per il Q3 è stato di 0,6 milioni di dollari. La direzione ha aumentato la guidance per le entrate 2025 del Cell Processing a 93,0–94,0 milioni di dollari e la guidance per le entrate totali (post vendita evo) a 95,0–96,0 milioni di dollari. L'azienda ha completato la vendita della sua attività evo cold chain per 25,5 milioni di dollari all'inizio di ottobre 2025.
BioLife Solutions (Nasdaq: BLFS) informó resultados del tercer trimestre de 2025 mostrando un crecimiento continuo en su negocio principal de procesamiento celular. Los ingresos por procesamiento celular aumentaron un 33% interanual a 25,4 millones de dólares, los ingresos totales fueron de 28,1 millones de dólares (un incremento del 31% interanual), y el EBITDA ajustado fue de 7,8 millones de dólares (28% de los ingresos). El beneficio neto GAAP para el Q3 fue de 0,6 millones de dólares. La dirección elevó la guía de ingresos para 2025 del procesamiento celular a 93,0–94,0 millones de dólares y la guía de ingresos totales (después de la venta evo) a 95,0–96,0 millones de dólares. La empresa completó la venta de su negocio evo de cadena de frío por 25,5 millones de dólares a principios de octubre de 2025.
BioLife Solutions (나스닥: BLFS)가 2025년 3분기 실적을 발표했고 핵심 세포 가공 사업에서 지속적인 성장을 보였습니다. 세포 가공 매출은 전년 동기 대비 33% 증가한 2540만 달러, 총 매출은 2810만 달러(전년 대비 31% 증가), 조정 EBITDA는 780만 달러(매출의 28%)였습니다. 3분기 GAAP 순이익은 60만 달러였습니다. 경영진은 2025년 세포 가공 매출 가이드를 9300만~9400만 달러로, EVO 매각 이후의 총매출 가이드를 9500만~9600만 달러로 상향했습니다. 회사는 2025년 10월 초 EVO 냉장 유통 사업을 2550만 달러에 매각하는 거래를 완료했습니다.
BioLife Solutions (Nasdaq: BLFS) a publié les résultats du T3 2025 montrant une croissance continue de son activité principale de traitement cellulaire. Le chiffre d'affaires du traitement cellulaire a augmenté de 33% sur un an pour atteindre 25,4 millions de dollars, le chiffre d'affaires total s'est établi à 28,1 millions de dollars (en hausse de 31% sur un an), et l'EBITDA ajusté est de 7,8 millions de dollars (28% du chiffre d'affaires). Le résultat net GAAP pour le T3 était de 0,6 million de dollars. La direction a relevé les prévisions de chiffre d'affaires 2025 pour le traitement cellulaire à 93,0–94,0 millions de dollars et les prévisions de chiffre d'affaires total (après la vente EVO) à 95,0–96,0 millions de dollars. L'entreprise a finalisé la vente de son activité evo cold chain pour 25,5 millions de dollars début octobre 2025.
BioLife Solutions (Nasdaq: BLFS) hat die Ergebnisse des Q3 2025 vorgelegt und ein weiterhin Wachstum im Kerngeschäft der Zellverarbeitung gezeigt. Der Umsatz aus der Zellverarbeitung stieg gegenüber dem Vorjahr um 33% auf 25,4 Mio. USD, der Gesamtertrag betrug 28,1 Mio. USD (plus 31% YoY), und das bereinigte EBITDA betrug 7,8 Mio. USD (28% des Umsatzes). Das GAAP-Nettoeinkommen für das Q3 betrug 0,6 Mio. USD. Das Management hob die Jahresprognose 2025 für den Zellverarbeitung-Umsatz auf 93,0–94,0 Mio. USD an und die Umsatzprognose insgesamt (nach dem EVO-Verkauf) auf 95,0–96,0 Mio. USD an. Das Unternehmen schloss den Verkauf seines EVO-Kühlketten-Geschäfts für 25,5 Mio. USD Anfang Oktober 2025 ab.
BioLife Solutions (ناسداك: BLFS) أبلغت عن نتائج الربع الثالث من 2025 مع إظهار نمو مستمر في نشاطها الأساسي لمعالجة الخلايا. إيرادات معالجة الخلايا ارتفعت بنسبة 33% على أساس سنوي لتصل إلى 25.4 مليون دولار، وكانت الإيرادات الإجمالية 28.1 مليون دولار (ارتفاع 31% على أساس سنوي)، وEBITDA المعدل كان 7.8 مليون دولار (28% من الإيرادات). صافي الدخل وفق المعايير GAAP للربع الثالث كان 0.6 مليون دولار. رفع الإدارة توجيهات إيرادات 2025 لمعالجة الخلايا إلى 93.0–94.0 مليون دولار وتوجيه الإيرادات الإجمالية (بعد بيع EVO) إلى 95.0–96.0 مليون دولار. أكملت الشركة بيع نشاط EVO لسلسلة التبريد بقيمة 25.5 مليون دولار في أوائل أكتوبر 2025.
- Cell Processing revenue +33% YoY to $25.4M
- Total revenue +31% YoY to $28.1M
- Adjusted EBITDA $7.8M (28% of revenue)
- Raised 2025 Cell Processing guidance to $93.0M–$94.0M
- Completed evo sale for $25.5M in October 2025
- Adjusted gross margin down to 64% from 67% due to $0.6M inventory reserve
- Nine-month GAAP net loss of $15.7M
- GAAP operating loss widened to $17.9M for nine months
Insights
Revenue and margin trends show clear operational improvement; guidance raised and divestiture simplifies the business profile.
BioLife reported Q3 cell processing revenue of
The company still shows pockets of caution: GAAP operating loss and year‑to‑date net loss remain material (
Watch upcoming quarterly results and the Q4 revenue cadence for confirmation that accelerated shipments were one‑time (Q3 included ~
Cell Processing revenue of
GAAP gross margin of
GAAP net income of
Raises 2025 full-year Cell Processing revenue guidance to
Conference call begins at 4:30 p.m. Eastern time today
Roderick de Greef, BioLife's Chairman and CEO, commented, "We delivered another strong quarter, with cell processing revenue up
"The divestiture of our evo cold chain logistics business in early October has reshaped BioLife into a leading pure-play cell processing company centered on our highest-value, recurring revenue franchises. This streamlined profile, solid financial position and market leading product portfolio provide a strong foundation for continued profitable growth and long-term value creation."
Third Quarter 2025 Business Highlights
- Our biopreservation media is utilized in approximately 250 ongoing commercially sponsored clinical trials in the
U.S. , representing a more than70% market share. This includes over 30 Phase III trials, or nearly80% of these late-stage trials. Our CellSeal vials and hPL products are used in over 35 clinical trials.
- Our biopreservation media is embedded in 16 unique commercial CGTs as of September 30, 2025, with expectations that approvals for 10 additional products, geographic expansions, earlier lines of treatment, or new indications will occur over the next 12 months. Our CellSeal cryogenic vials and hPL products are embedded into four approved therapies.
- On October 6, 2025, we completed the sale of evo, a previously wholly owned cold chain logistics subsidiary operated under SAVSU Cleo Technologies, LLC (formerly known as SAVSU Technologies, Inc.), for an aggregate sales price of
$25
Third Quarter 2025 Financial Results
BioLife Solutions is presenting various financial metrics under
REVENUE
- Total revenue for the third quarter of 2025 was
$28.1 million $6.7 million 31% , from$21.4 million $2.6 million 10% , from the second quarter of 2025.
-
- Cell Processing revenue was
$25.4 million $6.3 million 33% , from the same period in 2024 and up$2.4 million 10% , from the second quarter of 2025. Growth was primarily due to strong demand from customers with commercially approved therapies. The quarter included approximately$1.3 million
- Cell Processing revenue was
-
- evo and Thaw platform revenue was
$2.7 million $0.4 million , or15% , from the same period in 2024 and up$0.2 million 10% , from the second quarter of 2025.
- evo and Thaw platform revenue was
- Total revenue for the nine months ended September 30, 2025 was
$77.4 million $17.9 million 30% , from$59.5 million
-
- Cell Processing platform revenue for the nine months ended September 30, 2025 was
$69.9 million $16.7 million 31% , from the same period in 2024. Growth was due to strong demand from customers with commercially approved therapies, as well as revenue from biopreservation media product that was originally expected to ship in Q4 2025, as mentioned above.
- Cell Processing platform revenue for the nine months ended September 30, 2025 was
-
- evo and Thaw platform revenue for the nine months ended September 30, 2025 was
$7.5 million $1.2 million , or19% , from the same period in 2024.
- evo and Thaw platform revenue for the nine months ended September 30, 2025 was
- Gross margin (GAAP) for the third quarter of 2025 was
62% compared with63% for the third quarter of 2024. Adjusted gross margin (non-GAAP) for the third quarter of 2025 was64% compared with67% for the third quarter of 2024. The decreases were due to an inventory reserve of approximately$0.6 million 2% of Q3 2025 revenue.
- Gross margin (GAAP) for the nine months ended September 30, 2025 was
62% compared with63% for the same period in 2024. Adjusted gross margin (non-GAAP) for the nine months ended September 30, 2025 was65% compared with67% for the same period in 2024. The decreases were due to the inventory reserve of approximately$0.6 million
OPERATING LOSS
- Operating loss (GAAP) for the third quarter of 2025 was
$0.1 million $0.4 million $1.3 million $0.2 million
- Operating loss (GAAP) for the nine months ended September 30, 2025 was
$17.9 million $5.0 million $1.7 million $3.0 million
NET INCOME / (LOSS)
- Net income (GAAP) for the third quarter of 2025 was
$0.6 million $0.5 million $2.0 million $34 thousand
- Net loss (GAAP) for the nine months ended September 30, 2025 was
$15.7 million $9.2 million $4.2 million $3.2 million
NET INCOME / (LOSS) PER SHARE
- Net income per share (GAAP) for the third quarter of 2025 was
$0.01 $0.01
- Net loss per share (GAAP) for the nine months ended September 30, 2025 was
$0.33 $0.20
ADJUSTED EBITDA
- Adjusted EBITDA, a non-GAAP measure, for the third quarter of 2025 was
$7.8 million 28% of revenue, compared with$5.0 million 23% of revenue, for the third quarter of 2024.
- Adjusted EBITDA, a non-GAAP measure, for the nine months ended September 30, 2025 was
$19.7 million 25% of revenue, compared with$11.6 million 19% of revenue, for the same period in 2024.
CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES
- Cash, cash equivalents, and marketable securities as of September 30, 2025, were
$98.4 million - The cash, cash equivalents, and marketable securities balance as of September 30, 2025 does not include any cash proceeds from the sale of evo in October 2025.
(As a result of presenting amounts in millions, rounding differences may exist in the percentages above.)
2025 Financial Guidance
Following the sale of its evo cold chain logistics business in early October, BioLife Solutions is updating its 2025 revenue guidance.
Total 2025 revenue guidance, adjusted for the sale of evo, is
- Cell Processing platform revenue: Raised to
$93.0 million $94.0 million $91.0 million $93.0 million 26% to28% .
- Removal of approximately
$8 million
Going forward, BioLife will report revenue as a single line item encompassing its entire product portfolio.
Management continues to expect 2025 gross margin (GAAP) in the low
Conference Call & Webcast
Management will discuss the Company's financial results, provide a general business update and answer questions during a conference call and live webcast today at 4:30 p.m. ET (1:30 p.m. PT).
To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at https://www.biolifesolutions.com/earnings. In addition, the conference call will be accessible by dialing toll-free 1-833-630-0431 or 1-412-317-1808 for international callers. A webcast replay will be available approximately two hours after the call ends and will be archived on https://www.biolifesolutions.com for 90 days.
About BioLife Solutions
BioLife is a leading developer and supplier of cell processing tools and services for the CGT market. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. For more information, please visit www.biolifesolutions.com, and follow BioLife on LinkedIn and X.
Cautions Regarding Forward Looking Statements
Certain statements contained in this press release are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "plans," "intend," "expects," "continue," "believes," "anticipates," "designed," and similar words are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of certain of these risks, uncertainties and other matters can be found in filings we make with the
Non-GAAP Measures of Financial Performance
To supplement our financial statements, which are presented on the basis of
We believe these non-GAAP financial measures are useful to investors in assessing our operating performance. We use these financial measures internally to evaluate our operating performance and for planning and forecasting of future periods. We also believe it is in the best interests of investors to provide this non-GAAP information.
While we believe these non-GAAP financial measures provide useful supplemental information to investors, there are limitations associated with the use of these non-GAAP financial measures. These non-GAAP financial measures may not be reported by competitors, and they may not be directly comparable to similarly titled measures of other companies due to differences in calculation methodologies. The non-GAAP financial measures are not an alternative to GAAP information and are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures. They should be used only as a supplement to GAAP information and should be considered only in conjunction with our consolidated financial statements prepared in accordance with GAAP.
Media & Investor Relations
At the Company
Troy Wichterman
Chief Financial Officer
(425) 402-1400
twichterman@biolifesolutions.com
Investors
Alliance Advisors IR
Jody Cain
(310) 691-7100
jcain@allianceadvisors.com
|
BIOLIFE SOLUTIONS, INC. |
|||||||
|
|
|||||||
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||
|
(In thousands, except per share and share data) |
2025 |
|
2024 |
|
2025 |
|
2024 |
|
|
|
|
|
|
|
|
|
|
Product revenue |
$ 26,250 |
|
$ 19,928 |
|
$ 72,258 |
|
$ 54,783 |
|
Service revenue |
26 |
|
20 |
|
122 |
|
119 |
|
Rental revenue |
1,791 |
|
1,443 |
|
5,049 |
|
4,637 |
|
Total product, rental, and service revenue |
28,067 |
|
21,391 |
|
77,429 |
|
59,539 |
|
Costs and operating expenses: |
|
|
|
|
|
|
|
|
Cost of product, rental, and service revenue (exclusive of Intangible asset |
10,146 |
|
7,400 |
|
27,288 |
|
20,100 |
|
General and administrative |
12,074 |
|
9,326 |
|
34,970 |
|
29,041 |
|
Sales and marketing |
2,528 |
|
2,507 |
|
7,857 |
|
7,366 |
|
Research and development |
2,709 |
|
1,893 |
|
7,633 |
|
5,997 |
|
IPR&D expense |
— |
|
— |
|
15,521 |
|
— |
|
Intangible asset amortization |
699 |
|
683 |
|
2,109 |
|
2,054 |
|
Total operating expenses |
28,156 |
|
21,809 |
|
95,378 |
|
64,558 |
|
Operating loss |
(89) |
|
(418) |
|
(17,949) |
|
(5,019) |
|
|
|
|
|
|
|
|
|
|
Other income (expense): |
|
|
|
|
|
|
|
|
Change in fair value of equity investments |
— |
|
— |
|
— |
|
(4,074) |
|
Interest income (expense), net |
508 |
|
(230) |
|
1,873 |
|
(695) |
|
Other income |
284 |
|
97 |
|
633 |
|
496 |
|
Total other income (expense), net |
792 |
|
(133) |
|
2,506 |
|
(4,273) |
|
|
|
|
|
|
|
|
|
|
Income (loss) before income tax (expense) benefit |
703 |
|
(551) |
|
(15,443) |
|
(9,292) |
|
Income tax (expense) benefit |
(82) |
|
80 |
|
(222) |
|
62 |
|
Net income (loss) from continuing operations |
$ 621 |
|
$ (471) |
|
$ (15,665) |
|
$ (9,230) |
|
|
|
|
|
|
|
|
|
|
Discontinued operations: |
|
|
|
|
|
|
|
|
Loss from discontinued operations before income tax expense |
— |
|
(1,180) |
|
— |
|
(23,247) |
|
Income tax expense |
— |
|
(52) |
|
— |
|
(166) |
|
Loss from discontinued operations |
$ — |
|
$ (1,232) |
|
$ — |
|
$ (23,413) |
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
$ 621 |
|
$ (1,703) |
|
$ (15,665) |
|
$ (32,643) |
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share - Basic: |
|
|
|
|
|
|
|
|
Continuing operations |
$ 0.01 |
|
$ (0.01) |
|
$ (0.33) |
|
$ (0.20) |
|
Discontinued operations |
$ — |
|
$ (0.03) |
|
$ — |
|
$ (0.51) |
|
Net income (loss) per share |
$ 0.01 |
|
$ (0.04) |
|
$ (0.33) |
|
$ (0.71) |
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share - Diluted: |
|
|
|
|
|
|
|
|
Continuing operations |
$ 0.01 |
|
$ (0.01) |
|
$ (0.33) |
|
$ (0.20) |
|
Discontinued operations |
$ — |
|
$ (0.03) |
|
$ — |
|
$ (0.51) |
|
Net income (loss) per share per share |
$ 0.01 |
|
$ (0.04) |
|
$ (0.33) |
|
$ (0.71) |
|
|
|
|
|
|
|
|
|
|
Weighted average shares used to compute income (loss) per share: |
|
|
|
|
|
|
|
|
Basic |
47,925,038 |
|
46,175,345 |
|
47,622,196 |
|
45,871,715 |
|
Diluted |
48,723,535 |
|
46,175,345 |
|
47,622,196 |
|
45,871,715 |
|
BIOLIFE SOLUTIONS, INC. |
|||||||
|
|
|||||||
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
||||
|
(In thousands) |
2025 |
|
2024 |
|
2025 |
|
2024 |
|
Net income (loss) |
$ 621 |
|
$ (1,703) |
|
$ (15,665) |
|
$ (32,643) |
|
Other comprehensive income |
59 |
|
347 |
|
106 |
|
137 |
|
Comprehensive income (loss) |
$ 680 |
|
$ (1,356) |
|
$ (15,559) |
|
$ (32,506) |
|
BIOLIFE SOLUTIONS, INC. |
|||
|
|
|||
|
|
September |
|
December 31, |
|
(In thousands) |
2025 |
|
2024 |
|
Cash, cash equivalents, and marketable securities |
$ 98,398 |
|
$ 109,212 |
|
Working capital |
99,420 |
|
116,027 |
|
Current assets |
126,566 |
|
148,761 |
|
Total assets |
392,081 |
|
399,487 |
|
Current liabilities |
27,146 |
|
32,734 |
|
Long-term obligations |
11,196 |
|
17,844 |
|
Accumulated deficit |
(350,766) |
|
(335,101) |
|
Total shareholders' equity |
$ 353,739 |
|
$ 348,909 |
|
BIOLIFE SOLUTIONS, INC. |
|||
|
|
|||
|
|
Nine Months Ended
|
||
|
(In thousands) |
2025 |
|
2024 |
|
Net cash provided by operating activities |
$ 15,199 |
|
$ 6,786 |
|
Net cash used in investing activities |
(72,676) |
|
(15,337) |
|
Net cash used in financing activities |
(8,428) |
|
(2,697) |
|
Effects of currency translation |
— |
|
(29) |
|
Net decrease in cash and cash equivalents |
$ (65,905) |
|
$ (11,277) |
|
|
|
|
|
|
Cash and cash equivalents – beginning of period |
$ 95,386 |
|
$ 35,438 |
|
Cash and cash equivalents – end of period |
29,481 |
|
24,161 |
|
|
|
|
|
|
Marketable securities |
68,917 |
|
15,095 |
|
|
|
|
|
|
Total cash, cash equivalents, and marketable securities |
$ 98,398 |
|
$ 39,256 |
|
BIOLIFE SOLUTIONS, INC. |
|||||||
|
|
|||||||
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||
|
(In thousands) |
2025 |
|
2024 |
|
2025 |
|
2024 |
|
Total revenues |
$ 28,067 |
|
$ 21,391 |
|
$ 77,429 |
|
$ 59,539 |
|
Cost of revenues |
(10,146) |
|
(7,400) |
|
(27,288) |
|
(20,100) |
|
COGS intangible asset amortization |
(596) |
|
(577) |
|
(1,794) |
|
(1,736) |
|
GROSS PROFIT |
$ 17,325 |
|
$ 13,414 |
|
$ 48,347 |
|
$ 37,703 |
|
GROSS MARGIN |
62 % |
|
63 % |
|
62 % |
|
63 % |
|
|
|
|
|
|
|
|
|
|
ADJUSTMENTS TO GROSS PROFIT: |
|
|
|
|
|
|
|
|
Inventory reserve costs |
— |
|
247 |
|
— |
|
247 |
|
Gain on disposal of assets |
— |
|
— |
|
(12) |
|
— |
|
Intangible asset amortization |
596 |
|
577 |
|
1,794 |
|
1,736 |
|
ADJUSTED GROSS PROFIT |
$ 17,921 |
|
$ 14,238 |
|
$ 50,129 |
|
$ 39,686 |
|
ADJUSTED GROSS MARGIN |
64 % |
|
67 % |
|
65 % |
|
67 % |
|
BIOLIFE SOLUTIONS, INC. |
|||||||
|
|
|||||||
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||
|
(In thousands) |
2025 |
|
2024 |
|
2025 |
|
2024 |
|
OPERATING EXPENSES |
$ 28,156 |
|
$ 21,809 |
|
$ 95,378 |
|
$ 64,558 |
|
|
|
|
|
|
|
|
|
|
ADJUSTMENTS TO OPERATING |
|
|
|
|
|
|
|
|
Cost of product, rental, and service |
(10,146) |
|
(7,400) |
|
(27,288) |
|
(20,100) |
|
Acquisition and divestiture costs(1) |
(367) |
|
(334) |
|
(1,308) |
|
(706) |
|
Severance costs |
(316) |
|
— |
|
(732) |
|
— |
|
IPR&D expense |
— |
|
— |
|
(15,521) |
|
— |
|
Intangible asset amortization |
(699) |
|
(683) |
|
(2,109) |
|
(2,054) |
|
Loss on disposal of assets |
— |
|
— |
|
10 |
|
— |
|
Other income |
— |
|
679 |
|
— |
|
979 |
|
ADJUSTED OPERATING EXPENSES |
$ 16,628 |
|
$ 14,071 |
|
$ 48,430 |
|
$ 42,677 |
|
|
|
|
(1) |
During the six months ended June 2025, we incurred |
|
BIOLIFE SOLUTIONS, INC. |
|||||||
|
|
|||||||
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||
|
(In thousands) |
2025 |
|
2024 |
|
2025 |
|
2024 |
|
OPERATING LOSS |
$ (89) |
|
$ (418) |
|
$ (17,949) |
|
$ (5,019) |
|
|
|
|
|
|
|
|
|
|
ADJUSTMENTS TO OPERATING LOSS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acquisition and divestiture costs(1) |
367 |
|
334 |
|
1,308 |
|
706 |
|
Severance costs |
316 |
|
— |
|
732 |
|
— |
|
IPR&D expense |
— |
|
— |
|
15,521 |
|
— |
|
Intangible asset amortization |
699 |
|
683 |
|
2,109 |
|
2,054 |
|
Gain on disposal of assets |
— |
|
— |
|
(10) |
|
— |
|
Other income |
— |
|
(679) |
|
— |
|
(979) |
|
Inventory reserve costs |
— |
|
247 |
|
— |
|
247 |
|
ADJUSTED OPERATING INCOME |
$ 1,293 |
|
$ 167 |
|
$ 1,711 |
|
$ (2,991) |
|
|
|
|
(1) |
During the six months ended June 2025, we incurred |
|
BIOLIFE SOLUTIONS, INC. |
|||||||
|
|
|||||||
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||
|
(In thousands) |
2025 |
|
2024 |
|
2025 |
|
2024 |
|
NET INCOME / (LOSS) FROM |
$ 621 |
|
$ (471) |
|
$ (15,665) |
|
$ (9,230) |
|
|
|
|
|
|
|
|
|
|
ADJUSTMENTS TO NET INCOME / |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acquisition and divestiture costs(1) |
367 |
|
334 |
|
1,308 |
|
706 |
|
Severance costs |
316 |
|
— |
|
732 |
|
— |
|
IPR&D expense |
— |
|
— |
|
15,521 |
|
— |
|
Intangible asset amortization |
699 |
|
683 |
|
2,109 |
|
2,054 |
|
Gain on disposal of assets |
— |
|
— |
|
(10) |
|
— |
|
Change in fair value of investments, |
(41) |
|
— |
|
(41) |
|
4,074 |
|
Income tax expense / (benefit) |
82 |
|
(80) |
|
222 |
|
(62) |
|
Other income |
— |
|
(679) |
|
— |
|
(979) |
|
Inventory reserve costs |
— |
|
247 |
|
— |
|
247 |
|
ADJUSTED NET INCOME |
$ 2,044 |
|
$ 34 |
|
$ 4,176 |
|
$ (3,190) |
|
|
|
|
(1) |
During the six months ended June 2025, we incurred |
|
BIOLIFE SOLUTIONS, INC. |
|||||||
|
|
|||||||
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||
|
(In thousands) |
2025 |
|
2024 |
|
2025 |
|
2024 |
|
NET INCOME / (LOSS) FROM |
$ 621 |
|
$ (471) |
|
$ (15,665) |
|
$ (9,230) |
|
|
|
|
|
|
|
|
|
|
ADJUSTMENTS: |
|
|
|
|
|
|
|
|
Interest (income) expense, net |
(508) |
|
230 |
|
(1,873) |
|
695 |
|
Accretion of available-for-sale investments |
(235) |
|
(88) |
|
(540) |
|
(408) |
|
Income tax expense / (benefit) |
82 |
|
(80) |
|
222 |
|
(62) |
|
Depreciation |
636 |
|
711 |
|
1,992 |
|
2,224 |
|
Intangible asset amortization |
699 |
|
683 |
|
2,109 |
|
2,054 |
|
EBITDA |
$ 1,295 |
|
$ 985 |
|
$ (13,755) |
|
$ (4,727) |
|
|
|
|
|
|
|
|
|
|
OTHER ADJUSTMENTS: |
|
|
|
|
|
|
|
|
Share-based compensation (non-cash) |
5,895 |
|
4,134 |
|
15,897 |
|
12,233 |
|
Acquisition and divestiture costs(1) |
367 |
|
334 |
|
1,308 |
|
706 |
|
Severance costs |
316 |
|
— |
|
732 |
|
— |
|
IPR&D expense |
— |
|
— |
|
15,521 |
|
— |
|
Gain on disposal of assets |
— |
|
— |
|
(10) |
|
— |
|
Change in fair value of investments, |
(41) |
|
— |
|
(41) |
|
4,074 |
|
Other income |
— |
|
(679) |
|
— |
|
(979) |
|
Inventory reserve costs |
— |
|
247 |
|
— |
|
247 |
|
ADJUSTED EBITDA |
$ 7,832 |
|
$ 5,021 |
|
$ 19,652 |
|
$ 11,554 |
|
% of Revenue |
28 % |
|
23 % |
|
25 % |
|
19 % |
|
|
|
|
(1) |
During the six months ended June 2025, we incurred |
As stated above, we anticipate the divestiture of evo to qualify and be presented as Discontinued Operations in our Annual Report on Form 10-K for the year ended December 31, 2025. Below we are presenting key financial results by quarter for the year ended December 31, 2024 and quarter ended September 30, 2025 exclusive of evo to provide an estimate of our financial profile on a continuing operations basis. This includes the non-GAAP measures Adjusted Gross Margin and Adjusted EBITDA.
We have not yet finalized the accounting for the divestiture of evo and therefore note that all results below are subject to a number of assumptions, and actual results may differ. We do not anticipate actual results to be materially different from those presented below.
|
BIOLIFE SOLUTIONS, INC. |
|||||||||
|
|
|||||||||
|
(In thousands) |
Q1 2024 |
|
Q2 2024 |
|
Q3 2024 |
|
Q4 2024 |
|
FY2024 |
|
Total revenues |
$ 16,485 |
|
$ 18,042 |
|
$ 19,405 |
|
$ 20,714 |
|
$ 74,646 |
|
Cost of revenues |
4,961 |
|
5,905 |
|
5,888 |
|
6,829 |
|
23,583 |
|
Gross profit |
11,524 |
|
12,137 |
|
13,517 |
|
13,885 |
|
51,063 |
|
General and administrative |
10,623 |
|
9,174 |
|
9,355 |
|
11,476 |
|
40,628 |
|
Sales and marketing |
2,180 |
|
2,325 |
|
2,340 |
|
2,087 |
|
8,932 |
|
Research and development |
1,159 |
|
1,243 |
|
1,166 |
|
1,183 |
|
4,751 |
|
Intangible asset amortization |
312 |
|
307 |
|
307 |
|
307 |
|
1,233 |
|
Operating (loss) income |
(2,750) |
|
(912) |
|
349 |
|
(1,168) |
|
(4,481) |
|
Other income (expense), net |
52 |
|
(4,245) |
|
(129) |
|
(24) |
|
(4,346) |
|
(Loss) income before income taxes |
(2,698) |
|
(5,157) |
|
220 |
|
(1,192) |
|
(8,827) |
|
Income tax (expense) benefit |
(17) |
|
(1) |
|
80 |
|
(24) |
|
38 |
|
(Loss) income from continuing |
$ (2,715) |
|
$ (5,158) |
|
$ 300 |
|
$ (1,216) |
|
$ (8,789) |
|
(In thousands) |
Q1 2025 |
|
Q2 2025 |
|
Q3 2025 |
|
YTD 2025 |
|
Total revenues |
$ 22,053 |
|
$ 23,438 |
|
$ 25,958 |
|
$ 71,449 |
|
Cost of revenues |
6,995 |
|
7,938 |
|
9,130 |
|
24,063 |
|
Gross profit |
15,058 |
|
15,500 |
|
16,828 |
|
47,386 |
|
General and administrative |
11,481 |
|
11,363 |
|
12,049 |
|
34,893 |
|
Sales and marketing |
2,443 |
|
2,577 |
|
2,386 |
|
7,406 |
|
Research and development |
1,439 |
|
1,965 |
|
2,097 |
|
5,501 |
|
Intangible asset amortization |
325 |
|
332 |
|
325 |
|
982 |
|
IPR&D expense |
— |
|
15,521 |
|
— |
|
15,521 |
|
Operating (loss) income |
(630) |
|
(16,258) |
|
(29) |
|
(16,917) |
|
Other income, net |
784 |
|
930 |
|
791 |
|
2,505 |
|
Income (loss) before income taxes |
154 |
|
(15,328) |
|
762 |
|
(14,412) |
|
Income tax (expense) benefit |
(14) |
|
(126) |
|
(82) |
|
(222) |
|
Income (loss) from continuing |
$ 140 |
|
$ (15,454) |
|
$ 680 |
|
$ (14,634) |
|
BIOLIFE SOLUTIONS, INC. |
|||||||||
|
|
|||||||||
|
(In thousands) |
Q1 2024 |
|
Q2 2024 |
|
Q3 2024 |
|
Q4 2024 |
|
FY2024 |
|
Total revenues |
$ 16,485 |
|
$ 18,042 |
|
$ 19,405 |
|
$ 20,714 |
|
$ 74,646 |
|
Cost of revenues |
(4,961) |
|
(5,905) |
|
(5,888) |
|
(6,829) |
|
(23,583) |
|
COGS intangible asset |
(246) |
|
(241) |
|
(241) |
|
(241) |
|
(969) |
|
Gross profit |
$ 11,278 |
|
$ 11,896 |
|
$ 13,276 |
|
$ 13,644 |
|
$ 50,094 |
|
Gross margin |
68 % |
|
66 % |
|
68 % |
|
66 % |
|
67 % |
|
|
|
|
|
|
|
|
|
|
|
|
ADJUSTMENTS TO GROSS |
|
|
|
|
|
|
|
|
|
|
Inventory reserve costs |
— |
|
— |
|
247 |
|
— |
|
247 |
|
Gain on disposal of assets |
— |
|
— |
|
— |
|
87 |
|
87 |
|
Intangible asset amortization |
246 |
|
241 |
|
241 |
|
241 |
|
969 |
|
ADJUSTED GROSS PROFIT |
$ 11,524 |
|
$ 12,137 |
|
$ 13,764 |
|
$ 13,972 |
|
$ 51,397 |
|
ADJUSTED GROSS MARGIN |
70 % |
|
67 % |
|
71 % |
|
67 % |
|
69 % |
|
(In thousands) |
Q1 2025 |
|
Q2 2025 |
|
Q3 2025 |
|
YTD 2025 |
|
Total revenues |
$ 22,053 |
|
$ 23,438 |
|
$ 25,958 |
|
$ 71,449 |
|
Cost of revenues |
(6,995) |
|
(7,938) |
|
(9,130) |
|
(24,063) |
|
COGS intangible asset |
(259) |
|
(267) |
|
(259) |
|
(785) |
|
Gross profit |
$ 14,799 |
|
$ 15,233 |
|
$ 16,569 |
|
$ 46,601 |
|
Gross margin |
67 % |
|
65 % |
|
64 % |
|
65 % |
|
|
|
|
|
|
|
|
|
|
ADJUSTMENTS TO GROSS |
|
|
|
|
|
|
|
|
Gain on disposal of assets |
(12) |
|
— |
|
— |
|
(12) |
|
Intangible asset amortization |
259 |
|
267 |
|
259 |
|
785 |
|
ADJUSTED GROSS PROFIT |
$ 15,046 |
|
$ 15,500 |
|
$ 16,828 |
|
$ 47,374 |
|
ADJUSTED GROSS MARGIN |
68 % |
|
66 % |
|
65 % |
|
66 % |
|
BIOLIFE SOLUTIONS, INC. |
|||||||||
|
|
|||||||||
|
(In thousands) |
Q1 2024 |
|
Q2 2024 |
|
Q3 2024 |
|
Q4 2024 |
|
FY2024 |
|
Income (loss) from continuing |
$ (2,715) |
|
$ (5,158) |
|
$ 300 |
|
$ (1,216) |
|
$ (8,789) |
|
|
|
|
|
|
|
|
|
|
|
|
ADJUSTMENTS: |
|
|
|
|
|
|
|
|
|
|
Interest expense, net |
200 |
|
316 |
|
226 |
|
24 |
|
766 |
|
Accretion of available-for-sale investments |
(183) |
|
(137) |
|
(88) |
|
(68) |
|
(476) |
|
Income tax expense (benefit) |
17 |
|
1 |
|
(80) |
|
24 |
|
(38) |
|
Depreciation |
172 |
|
159 |
|
151 |
|
161 |
|
643 |
|
Intangible asset amortization |
312 |
|
307 |
|
307 |
|
307 |
|
1,233 |
|
EBITDA |
$ (2,197) |
|
$ (4,512) |
|
$ 816 |
|
$ (768) |
|
$ (6,661) |
|
|
|
|
|
|
|
|
|
|
|
|
OTHER ADJUSTMENTS: |
|
|
|
|
|
|
|
|
|
|
Share-based compensation (non- |
3,886 |
|
3,730 |
|
3,918 |
|
3,748 |
|
15,282 |
|
Acquisition and divestiture costs |
237 |
|
134 |
|
334 |
|
540 |
|
1,245 |
|
(Gain) loss on disposal of assets |
— |
|
— |
|
— |
|
129 |
|
129 |
|
Change in fair value of |
— |
|
4,074 |
|
— |
|
— |
|
4,074 |
|
Other income |
— |
|
(300) |
|
(679) |
|
— |
|
(979) |
|
Inventory reserve costs |
— |
|
— |
|
247 |
|
— |
|
247 |
|
ADJUSTED EBITDA FROM |
$ 1,926 |
|
$ 3,126 |
|
$ 4,636 |
|
$ 3,649 |
|
$ 13,337 |
|
% of Revenue |
12 % |
|
17 % |
|
24 % |
|
18 % |
|
18 % |
|
(In thousands) |
Q1 2025 |
|
Q2 2025 |
|
Q3 2025 |
|
YTD 2025 |
|
Income (loss) from continuing |
$ 140 |
|
$ (15,454) |
|
$ 680 |
|
$ (14,634) |
|
|
|
|
|
|
|
|
|
|
ADJUSTMENTS: |
|
|
|
|
|
|
|
|
Interest income, net |
(683) |
|
(684) |
|
(508) |
|
(1,875) |
|
Accretion of available-for-sale investments |
(105) |
|
(200) |
|
(235) |
|
(540) |
|
Income tax expense (benefit) |
14 |
|
126 |
|
82 |
|
222 |
|
Depreciation |
185 |
|
200 |
|
203 |
|
588 |
|
Intangible asset amortization |
325 |
|
332 |
|
325 |
|
982 |
|
EBITDA |
$ (124) |
|
$ (15,680) |
|
$ 547 |
|
$ (15,257) |
|
|
|
|
|
|
|
|
|
|
OTHER ADJUSTMENTS: |
|
|
|
|
|
|
|
|
Share-based compensation (non- |
3,982 |
|
5,707 |
|
5,779 |
|
15,468 |
|
Acquisition and divestiture costs |
1,001 |
|
(59) |
|
367 |
|
1,309 |
|
Severance costs |
416 |
|
— |
|
316 |
|
732 |
|
IPR&D expense |
— |
|
15,521 |
|
— |
|
15,521 |
|
(Gain) loss on disposal of assets |
(10) |
|
— |
|
— |
|
(10) |
|
Change in fair value of |
— |
|
— |
|
(41) |
|
(41) |
|
ADJUSTED EBITDA FROM |
$ 5,265 |
|
$ 5,489 |
|
$ 6,968 |
|
$ 17,722 |
|
% of Revenue |
24 % |
|
23 % |
|
27 % |
|
25 % |
View original content to download multimedia:https://www.prnewswire.com/news-releases/biolife-solutions-reports-third-quarter-2025-financial-results-302607803.html
SOURCE BioLife Solutions, Inc.
FAQ
What were BioLife (BLFS) Q3 2025 revenues and growth rates?
How profitable was BioLife (BLFS) in Q3 2025 and what was adjusted EBITDA?
How did the sale of evo affect BioLife (BLFS) 2025 guidance?
What drove BioLife (BLFS) Q3 2025 revenue growth?
What margin trends did BioLife (BLFS) report in Q3 2025?
Where can investors access BioLife (BLFS) Q3 2025 earnings webcast?
